Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
Article 2023 en
Authors
OT
Olivier Trédan
MT
Maud Toulmonde
CT
Christophe Le Tourneau
Abstract
1 min read
Sorafenib showed activity in progressive patients with solid tumors harboring somatic genomic alterations in sorafenib-targeted genes. Continuing sorafenib when SD is achieved improves PFR compared to interruption.
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montané, Antoîne Italiano, Isabelle Ray‐Coquard, Christelle de la Fouchardière, François Bertucci, Anthony Gonçalvès, Carlos Gomez‐Roca, Benoît You, Valéry Attignon, Sandrine Boyault, Philippe A. Cassier, Armelle Dufresne, Séverine Tabone‐Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenaëlle Garin, Jean Yves Blay, David Pérol
Pippa Newell, Sara Toffanin, Augusto Villanueva, Derek Y. Chiang, Beatriz Mínguez, Laia Cabellos, Radoslav Savić, Yujin Hoshida, Kiat Hon Lim, Pedro Melgar‐Lesmes, Steven Yea, Judit Peix, Kemal Denız, Maria Isabel Fiel, Swan N. Thung, Clara Alsinet, Victoria Tovar, Vincenzo Mazzaferro, Jordi Bruix, Sasan Roayaie, Myron Schwartz, Scott L. Friedman, Josep M. Llovet
Riccardo Lencioni, Josep M. Llovet, Guohong Han, Won Young Tak, Jiamei Yang, Alfredo Guglielmi, Seung Woon Paik, María Reig, Do Young Kim, Gar-Yang Chau, Angelo Luca, L Ruíz del Arbol, Marie-Aude LeBerre, Woody Niu, Kate Nicholson, Gerold Meinhardt, Jordi Bruix
Sophie Cousin, Jean Yves Blay, Irene García, Johann S. de Bono, Christophe Le Tourneau, Víctor Moreno, José Trigo, Christine L. Hann, Arun Azad, Seock‐Ah Im, Geraldine Ferron‐Brady, Antara Datta, Yuehui Wu, Thierry Horner, Brandon E. Kremer, Arindam Dhar, Peter J. O’Dwyer, Geoffrey I. Shapiro, Sarina A. Piha‐Paul
Discussion(0)
No comments yet. Be the first to comment.